低级别前列腺癌连续分子分析评估肿瘤升级:纵向队列研究
BACKGROUND: The potential for low-grade (grade group 1 [GG1]) prostate cancer (PCa) to progress to high-grade disease remains unclear. OBJECTIVE: To interrogate the molecular and biological features of low-grade PCa serially over time.…
要点
- 低级别前列腺癌重复分子检测显示克隆演进可能是肿瘤升级机制之一。
- 追踪靶向活检的分子一致性支持聚焦再采样策略的可行性。
- 主动监测期间应重视定期活检以监测肿瘤升级。
核心结论
- 重复分子评估提示克隆演进可能是低级别前列腺癌升级的机制之一。
研究设计与样本
- 对追踪肿瘤灶进行磁共振/超声融合活检的电子追踪与再采样,中位间隔11个月。
主要发现
- 63例(95% vs 预期50%,p < 0.001)初次与重复活检的IHC ERG融合状态一致。
- 13例ERG+患者中9例(69%)RNAseq融合及亚型表达一致。
- 15例升级且两时间点数据完整的患者中,整合DNA/RNAseq分析至少5例有克隆共享证据。
临床怎么用
- 对主动监测的低级别前列腺癌患者,定期活检是监测肿瘤升级的重要组成部分。
局限性
- 样本量有限且采用靶向测序。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The potential for low-grade (grade group 1 [GG1]) prostate cancer (PCa) to progress to high-grade disease remains unclear. OBJECTIVE: To interrogate the molecular and biological features of low-grade PCa serially over time. DESIGN, SETTING, AND PARTICIPANTS: Nested longitudinal cohort study in an academic active surveillance (AS) program. Men were on AS for GG1 PCa from 2012 to 2017. INTERVENTION: Electronic tracking and resampling of PCa using magnetic resonance imaging/ultrasound fusion biopsy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: ERG immunohistochemistry (IHC) and targeted DNA/RNA next-generation sequencing were performed on initial and repeat biopsies. Tumor clonality was assessed. Molecular data were compared between men who upgraded and those who did not upgrade to GG ≥ 2 cancer. RESULTS AND LIMITATIONS: Sixty-six men with median age 64 yr (interquartile range [IQR], 59-69) and prostate-specific antigen 4.9 ng/mL (IQR, 3.3-6.4) underwent repeat sampling of a tracked tumor focus (median interval, 11 mo; IQR, 6-13). IHC-based ERG fusion status was concordant at initial and repeat biopsies in 63 men (95% vs expected 50%, p < 0.001), and RNAseq-based fusion and isoform expression were concordant in nine of 13 (69%) ERG+ patients, supporting focal resampling. Among 15 men who upgraded with complete data at both time points, integrated DNA/RNAseq analysis provided evidence of shared clonality in at least five cases. Such cases could reflect initial undersampling, but also support the possibility of clonal temporal progression of low-grade cancer. Our assessment was limited by sample size and use of targeted sequencing. CONCLUSIONS: Repeat molecular assessment of low-grade tumors suggests that clonal progression could be one mechanism of upgrading. These data underscore the importance of serial tumor assessment in men pursuing AS of low-grade PCa. PATIENT SUMMARY: We performed targeted rebiopsy and molecular testing of low-grade tumors on active surveillance. Our findings highlight the importance of periodic biopsy as a component of monitoring for cancer upgrading during surveillance.
引用
- Salami SS, Tosoian JJ, Nallandhighal S, et al. Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study. Eur Urol. 2020. PMID: 32631746. doi:10.1016/j.eururo.2020.06.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。